drugset / Trial / NCT04865458
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies
Timeline
- Start
- 2021-04-01
- Primary completion
- 2022-09-21
- Completion
- 2022-09-21
Outcome
Outcome not reported
Stopped (Business): “Adjustment to the sponsor's development strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HEC89736 | Unknown | 25 mg | — |
| Subject | HEC89736 | Unknown | 50 mg | — |
| Subject | HEC89736 | Unknown | 100 mg | — |
| Subject | HEC89736 | Unknown | 150 mg | — |
| Subject | HEC89736 | Unknown | 200 mg | — |